MedTrace Logo

Effects of Standardized Boswellia Carterii Extract on Irritable Bowel Syndrome Patients

NCT07576634 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-08

No results posted yet for this study

Summary

Irritable bowel syndrome (IBS) is a common condition that affects the stomach and intestines. It can cause abdominal pain, bloating, diarrhea, constipation, and changes in bowel habits, which may reduce a person's quality of life. Many people with IBS do not achieve complete symptom relief with standard treatments.

The purpose of this study is to evaluate whether a standardized Boswellia extract, combined with structured patient education, can help improve IBS symptoms and quality of life. Boswellia is a herbal extract that may help reduce inflammation and digestive discomfort.

In this study, 60 adults aged 18-39 years with moderate IBS were enrolled at Mansoura University Hospitals, Egypt. Participants received 500 mg of standardized Boswellia extract twice daily for 30 days and attended educational sessions about IBS self-management, including symptom control and healthy lifestyle practices.

Researchers evaluated abdominal pain, bloating, bowel habits, other gastrointestinal symptoms, and quality of life at the start of the study, after one week, and after one month to determine whether the intervention improved IBS symptoms and daily functioning.

Conditions

  • Irritable Bowel Syndrome

Interventions

DRUG

Boswellia carterii Extract

A soft gelatin capsule containing 500 mg of standardized Boswellia extract (containing more than 65% Boswellia acids) was administered orally twice daily with meals for a duration of 30 days. The researcher met with the participants five times per week at the outpatient clinics of Mansoura University Hospitals. During these meetings, participants were instructed on the proper administration of the capsules and were informed about potential side effects, including headache, diarrhea, renal complications, weight gain, osteoporosis, increased risk of infection, and high cost. In addition, the researcher conducted weekly follow-up phone calls, particularly during the first week of treatment, to assess the occurrence of any allergic reactions or adverse effects related to the Boswellia capsules. These follow-ups also aim to monitor adherence to the intervention, identify any missed doses, and obtain feedback regarding participants perceived improvement.

OTHER

Educationntal program for IBS patie

The researchers analyzed the findings from the assessment phase to identify gaps in knowledge and areas requiring improvement. Based on this analysis, the program's objectives and content were designed to address the specific educational needs of the IBS patients. All potential participants underwent an initial assessment to ensure that they met the inclusion criteria and did not meet any of the exclusion criteria. Demographic characteristics and relevant health-related data were collected from participants on the first day of the study using data collection tools as mentioned above. Educational sessions were provided to participants regarding irritable bowel syndrome (IBS) and the importance of Boswellia in the management of IBS

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-12-30
Completion
2026-01-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07576634 on ClinicalTrials.gov